Among a range of plasma biomarkers, measures of phosphorylated tau (p-tau) at amino acid 217 (p-tau217) have demonstrated considerable potential for detection of AD pathology, rivalling the gold-standards of amyloid-beta (Aβ) PET and cerebrospinal fluid (CSF)2. Here, MAPT is linked to Alzheimer disease.